The company’s pharmaceutical business reported a 15 percent hike in sales compared to 2022’s first quarter. Its brand and specialty drugs drove most of the final sales numbers, which was $39.8 billion last year and $45.8 billion this quarter, according to Cardinal Health.
Its medical segment fell 9 percent from $4.1 billion to $3.8 billion, which the devicemaker said was “primarily due to PPE pricing and volumes.”
Cardinal Health also attributed part of the loss to less investment in its Cordis business, a cardiology and endovascular device business it bought from Johnson & Johnson in 2015 for nearly $2 billion. Cardinal then sold it in 2021 for about $1 billion.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.